Evidence from preclinical studies suggests that the competitive HMG-CoA reductase (HMGCR) inhibitors universally known as 'statins,' in addition to being powerful drugs that reduce cholesterol and improve cardiovascular risk, also have promising antitumor properties. Statins appear to enhance the treatment outcome of various cancers before and concurrent with other cancer treatment interventions. Glioblastoma multiforme (GBM), a particularly invasive cerebral tumor associated with high mortality, holds a poor median overall survival (OS) of around one year after surgical resection followed by concurrent radiation and chemotherapy. Recently, statins have increasingly appeared as potential adjuvant drugs for the treatment of GBM because of their potential to suppress cell growth, survival, migration, metastasis, inflammation, angiogenesis, and promote apoptosis during both in vitro and in vivo studies. However, the clinical outcomes of statins on the survival of patients with GBM are still controversial. This study aims to review and address some of the documented effects of statin drugs when focusing entirely on cancer treatment, especially GBM, including concurrent statin therapy with chemotherapeutic agents.

临床前研究的证据表明，竞争性 HMG-CoA 还原酶 (HMGCR) 抑制剂通常被称为“他汀类药物”，除了是降低胆固醇和改善心血管风险的强效药物外，还具有良好的抗肿瘤特性。他汀类药物似乎可以在其他癌症治疗干预之前和同时增强各种癌症的治疗结果。多形性胶质母细胞瘤 (GBM) 是一种与高死亡率相关的特别侵袭性脑肿瘤，在手术切除后同时进行放疗和化疗后，中位总生存期 (OS) 较差，约为一年。最近，他汀类药物越来越多地成为治疗 GBM 的潜在辅助药物，因为它们具有抑制细胞生长、存活、迁移、转移、炎症、血管生成、体外和体内研究。然而，他汀类药物对GBM患者生存率的临床结果仍存在争议。本研究旨在回顾和解决他汀类药物在完全关注癌症治疗（尤其是 GBM）时的一些已证实的影响，包括与化疗药物同时进行的他汀类药物治疗。